Paper - WANFANG MED ONLINE

You Position: Home > Paper

From MAFLD to hepatocellular carcinoma and everything in between

( views:89, downloads:0 )

Author:: No author available

Journal Title:: Chinese Medical Journal

Issue:: 5

DOI:: 10.1097/CM9.0000000000002089

Key Word:: Metabolic (dysfunction) associated fatty liver disease;Liver disease;Liver cancer;Metabolic (dysfunction) associated fatty liver disease;Liver disease;Liver cancer

Abstract： Metabolic (dysfunction) associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is the most common cause of chronic liver disease worldwide. Many risk factors contribute to the pathogenesis of MAFLD with metabolic dysregulation being the final arbiter of its development and progression. MAFLD poses a substantial economic burden to societies, which based on current trends is expected to increase over time. Numerous studies have addressed various aspects of MAFLD from its risk associations to its economic and social burden and clinical diagnosis and management, as well as the molecular mechanisms linking MAFLD to end-stage liver disease and hepatocellular carcinoma. This review summarizes current understanding of the pathogenesis of MAFLD and related diseases, particularly liver cancer. Potential therapeutic agents for MAFLD and diagnostic biomarkers are discussed.

Reference

[1]KATRIEN VEKEMANS,Filip Braet.Structural and Functional Aspects of the Liver and Liver Sinusoidal Cells in Relation to Colon Carcinoma Metastasis[J].2005,(33).
[2]Chris Estes,Henry L. Y. Chan,Rong N. Chien,etc.Modelling NAFLD disease burden in four Asian regions—2019‐2030[J].2020,51(8).
[3]Sylvie,Rabot.Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism.[J].2010,24.
[4]Diletta,Overi,Guido,Carpino,Antonio,Franchitto,etc.Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis.[J].2020,9(3).
[5]Margini, Cristina,Dufour, Jean F..The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment[J].2016,36(3).
[6]Clouston,A.D.,Williams,M.J.,Forbes,S.J..Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion[J].2014,146(2).
[7]Mark Benedict,Xuchen Zhang.Non-alcoholic fatty liver disease:An expanded review[J].2017,(16).
[8]Zhang, Yingzhen N.,Fowler, Kathryn J.,Hamilton, Gavin,etc.Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging[J].2018,91(1089).
[9]Gary B. Huffnagle,Mairi C. Noverr.Does the microbiota regulate immune responses outside the gut?[J].2004,12(12).
[10]Itziar, Frades,Erik, Andreasson,Jose Maria, Mato,etc.Integrative genomic signatures of hepatocellular carcinoma derived from nonalcoholic Fatty liver disease.[J].2015,10.
[11]Rafael S.Rios,Kenneth I.Zheng,Ming-Hua Zheng.Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma[J].2021,134(24).
[12]Amedeo Lonardo,Fabio Nascimbeni,Stefano Ballestri,etc.Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps[J].2019,70(4).
[13]LeRoy,T.,Llopis,M.,Lepage,P.,etc.Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice[J].2013,62(12).
[14]Jin,Wang,Wanping,He,Ping-Ju,Tsai,etc.Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease.[J].2020,19(1).
[15]Eslam, Mohammed,Sanyal, Arun J.,George, Jacob.Toward More Accurate Nomenclature for Fatty Liver Diseases[J].2019,157(3).
[16]Christopher Leung,Sern Wei Yeoh,Desmond Patrick,etc.Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease[J].2015,(4).
[17].The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis.[J].2017.
[18]Eréndira Villanueva-Ortega,María José Garcés-Hernández,Arturo Herrera-Rosas,etc.Gender-specific differences in clinical and metabolic variables associated with NAFLD in a Mexican pediatric population[J].2019,18(5).
[19]Schuster, Susanne,Cabrera, Daniel,Arrese, Marco,etc.Triggering and resolution of inflammation in NASH[J].2018,15(6).
[20]Jessica K Dyson,Quentin M Anstee,Stuart McPherson.Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging[J].2014,5(3).
[21]Hae-Ki, Min,Faridoddin, Mirshahi,Aurora, Verdianelli,etc.Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease.[J].2015,308.
[22]Sagnelli, Evangelista,Macera, Margherita,Russo, Antonio,etc.Epidemiological and etiological variations in hepatocellular carcinoma[J].2020,48(1).
[23]Brown, Gregory Thomas,Kleiner, David E..Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J].2016,65(8).
[24]Keisaku Sato,Marco Marzioni,Fanyin Meng,etc.Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances[J].2019,69(1).
[25]G Craig, Wood,Xin, Chu,George, Argyropoulos,etc.A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains.[J].2017,7(Spec ).
[26]Guobin He,Michael Karin.NF-κB and STAT3-key players in liver inflammation and cancer[J].2011,(1).
[27]Anstee Quentin M.,Targher Giovanni,Day Christopher P..Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis[J].2013,10(6).
[28]Lili,Niu,Philipp E,Geyer,Nicolai J,Wewer Albrechtsen,etc.Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease.[J].2019,15(3).
[29]Leon A,Adams,Stuart K,Roberts,Simone I,Strasser,etc.Nonalcoholic fatty liver disease burden: Australia, 2019-2030.[J].2020.
[30]Dapito,D.,Mencin,A.,Gwak,G.-Y.,etc.Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4[J].2012,21(4).
[31]Gopanandan,Parthasarathy,Xavier,Revelo,Harmeet,Malhi.Pathogenesis of Nonalcoholic Steatohepatitis: An Overview.[J].2020,4(4).
[32]Shin Yoshimoto,Tze Mun Loo,Koji Atarashi,etc.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J].2013,499(Jul.4 TN.7456).
[33]Carmelo,Luci,Manon,Bourinet,Pierre S,Leclère,etc.Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies.[J].2020,11.
[34]Seshachalam, Veerabrahma Pratap,Sekar, Karthik,Hui, Kam M..Insights into the etiology-associated gene regulatory networks in hepatocellular carcinoma from The Cancer Genome Atlas[J].2018,33(12).
[35]Wen-Ce Zhou,Quan-Bao Zhang,Liang Qiao.Pathogenesis of liver cirrhosis[J].2014,(23).
[36]Ram\u00f3n Bataller,David A. Brenner.Liver fibrosis[J].2008,115(2).
[37]Omar Ramos-Lopez,Erika Martinez-Lopez,Sonia Roman,etc.Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico[J].2015,(41).
[38]Marengo, Andrea,Rosso, Chiara,Bugianesi, Elisabetta.Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis[J].2016,67.
[39]Stavros Bashiardes,Hagit Shapiro,Shachar Rozin,etc.Non-alcoholic fatty liver and the gut microbiota[J].2016,(9).
[40]Carpino, Guido,Renzi, Anastasia.Role of Hepatic Progenitor Cells in Nonalcoholic Fatty Liver Disease Development: Cellular Cross-Talks and Molecular Networks.[J].2013,14(10).
[41]Sabine H?rist-Kollmann,Jeanette Strametz-Juranek,Sabine H?rist-Kollmann,etc.Female Dietary Patterns and the Pathogenesis of NAFLD:[J].2018,2(2).
[42]Sanyal,A.J.,Lavine,J.E.,Diehl,A.M.,etc.The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J].2012,55(6).
[43]Daniel Q Huang,Hashem B El-Serag,Rohit Loomba.Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.[J].2021,18(4).
[44]Geoffrey C, Farrell,Derrick, van Rooyen,Lay, Gan,etc.NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.[J].2012,6.
[45]Michelotti,G.A.,Machado,M.V.,Diehl,A.M..NAFLD, NASH and liver cancer[J].2013,10(11).
[46]Carpino, Guido,Del Ben, Maria,Pastori, Daniele,etc.Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD[J].2020,72(2).
[47]Ding, Chen,Li, Yanyan,Guo, Feifei,etc.A Cell-type-resolved Liver Proteome[J].2016,15(10).
[48]Sonia, Michail,Malinda, Lin,Mark R, Frey,etc.Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease.[J].2015,91.
[49]Kohei Oda,Hirofumi Uto,Seiichi Mawatari,etc.Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies[J].2015,8(1).
[50]Park, EJ,Lee, JH,Yu, GY,etc.Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression[J].2010,140(2).
[51]Pablo J.Giraudi,Adam M.Stephenson,Claudio Tiribelli,etc.Novel high-throughput applications for NAFLD diagnostics and biomarker discovery[J].2021,(1).
[52]Zobair M, Younossi,Aaron B, Koenig,Dinan, Abdelatif,etc.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.[J].2016.
[53]Geoffrey C. Farrell,Geoffrey C. Farrell,Claire Z. Larter.Nonalcoholic fatty liver disease: From steatosis to cirrhosis[J].2006,43(S1).
[54]CombsJr.,G.F.,Liu,J.,Jackson,M.I.,etc.Fatty liver accompanies an increase in lactobacillus species in the hind gut of C57BL/6 mice fed a high-fat diet[J].2013,143(5).
[55]Li Fuxi,Ye Junzhao,Shao Congxiang,etc.Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis[J].2021,20(1).
[56].Burden of non-alcoholic fatty liver disease in Australia.[J].2018,331(Spec).
[57]Ozlem Kutlu,Humeyra Nur Kaleli,Ebru Ozer.Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma[J].2018,2018.
[58]Phisalprapa Pochamana,Prasitwarachot Ratthanon,Kositamongkol Chayanis,etc.Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand[J].2021,21(1).
[59]Mireia, López-Riera,Isabel, Conde,Guillermo, Quintas,etc.Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers.[J].2018,8(1).
[60]Casola G,Lavine JE,Aguirre DA,etc.Fatty liver: imaging patterns and pitfalls.[J].2006,26(6).
[61]Mohammed Eslam,Arun J. Sanyal,Jacob George.MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease[J].2020,158(7).
[62]On behalf of the National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of,Cai Wei,Feng Chen Dong,etc.Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)[J].2019,20(4).
[63]Younossi, Zobair M.,Rinella, Mary E.,Sanyal, Arun J.,etc.From NAFLD to MAFLD: Implications of a Premature Change in Terminology[J].2021,73(3).
[64]Reimer, Katharina C.,Wree, Alexander,Roderbursi, Christoph,etc.New drugs for NAFLD: lessons from basic models to the clinic[J].2020,14(1).
[65]Chris, Estes,Quentin M, Anstee,Maria Teresa, Arias-Loste,etc.Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.[J].2018,(Spec ).
[66]Kingwell Katie.Docking downstream to treat myasthenia[J].2021,20(8).